全身化疗下晚期肝外胆管癌患者常规额外胆管内射频消融与光动力疗法的比较
Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
作者信息
Möhring Christian, Khan Oliver, Zhou Taotao, Sadeghlar Farsaneh, Mahn Robert, Kaczmarek Dominik J, Dold Leona, Toma Marieta, Marinova Milka, Glowka Tim R, Matthaei Hanno, Manekeller Steffen, Kalff Jörg C, Strassburg Christian P, Weismüller Tobias J, Gonzalez-Carmona Maria A
机构信息
Department of Medicine I, University Hospital of Bonn, Bonn, Germany.
Department of Pathology, University Hospital of Bonn, Bonn, Germany.
出版信息
Front Oncol. 2023 Aug 29;13:1227036. doi: 10.3389/fonc.2023.1227036. eCollection 2023.
BACKGROUND AND AIMS
Extrahepatic cholangiocarcinoma (eCCA) remains a malignancy with a dismal prognosis. The first-line standard of care includes systemic chemotherapy (SC) and biliary drainage through stenting. Endobiliary ablative techniques, such as photodynamic therapy (ePDT) and radio-frequency ablation (eRFA), have demonstrated feasibility and favorable survival data. This study aimed to compare the oncologic outcome in patients treated with SC and concomitant eRFA or ePDT.
METHOD
All patients with eCCA were evaluated for study inclusion. Sixty-three patients receiving a combination of SC and at least one endobiliary treatment were retrospectively compared.
RESULTS
Patients were stratified into three groups: SC + ePDT (n = 22), SC + eRFA (n = 28), and SC + ePDT + eRFA (n = 13). The median overall survival (OS) of the whole cohort was 14.2 months with no statistically significant difference between the three therapy groups but a trend to better survival for the group receiving ePDT as well as eRFA, during SC (ePDT + SC, 12.7 months; eRFA + SC, 13.8 months; ePDT + eRFA + SC, 20.2 months; p = 0.112). The multivariate Cox regression and subgroup analysis highlighted the beneficial effect of eRFA on OS. Overall, combined therapy was well tolerated. Only cholangitis occurred more often in the SC + eRFA group.
CONCLUSION
Additional endobiliary ablative therapies in combination with SC were feasible. Both modalities, eRFA and ePDT, showed a similar benefit in terms of survival. Interestingly, patients receiving both regimes showed the best OS indicating a possible synergism between both ablative therapeutic techniques.
背景与目的
肝外胆管癌(eCCA)仍然是一种预后很差的恶性肿瘤。一线标准治疗包括全身化疗(SC)和通过支架置入进行胆道引流。胆管内消融技术,如光动力疗法(ePDT)和射频消融(eRFA),已证明具有可行性且生存数据良好。本研究旨在比较接受SC联合eRFA或ePDT治疗的患者的肿瘤学结局。
方法
对所有eCCA患者进行纳入研究评估。回顾性比较63例接受SC联合至少一种胆管内治疗的患者。
结果
患者被分为三组:SC + ePDT(n = 22)、SC + eRFA(n = 28)和SC + ePDT + eRFA(n = 13)。整个队列的中位总生存期(OS)为14.2个月,三个治疗组之间无统计学显著差异,但在SC期间接受ePDT以及eRFA的组有生存更好的趋势(ePDT + SC,12.7个月;eRFA + SC,13.8个月;ePDT + eRFA + SC,20.2个月;p = 0.112)。多变量Cox回归和亚组分析突出了eRFA对OS的有益作用。总体而言,联合治疗耐受性良好。仅胆管炎在SC + eRFA组中更常发生。
结论
SC联合额外的胆管内消融治疗是可行的。eRFA和ePDT这两种方式在生存方面显示出相似的益处。有趣的是,接受两种治疗方案的患者显示出最佳的OS,表明两种消融治疗技术之间可能存在协同作用。